REG - Avacta Group PLC - Notice of Results <Origin Href="QuoteRef">AVTG.L</Origin>

AvactaAnnouncement

07/09/2017 07:09

RNS Number : 0204Q
Avacta Group PLC
07 September 2017
07 September 2017
Avacta Group plc
("Avacta", the "Group" or the "Company")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, will announce its financial results for the year ended 31 July 2017 on Wednesday, 4 October 2017.
Enquiries:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
www.avacta.com
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane - Corporate Broking
WG Partners
David Wilson
Nigel Barnes
Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk
Media Enquiries
FTI Consulting
Simon Conway / Natalie Garland-Collins
Tel: +44 (0) 203 727 1000
avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. 
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORSSLFLMFWSESU